CONTENTS VOL. 7, 1989

Introduction to 5-FU symposium

In vivo ^{19}F nuclear magnetic resonance spectroscopy: a potential monitor of 5-fluorouracil pharmacokinetics and metabolism – J.L. Evelhoch 5

Cellular pharmcology of fluorinated pyramidines *in vivo* in man – J.S. Kovach, R.W. Beart Jr. 13

Folinic acid modulation of fluorouracil: Tissue kinetics of bolus administration – C.P. Spears, B.G. Gustavsson, R. Frösing 27

5-Fluorouracil containing combinations in murine tumor systems – T.H. Corbeth, M-C. Bissery, P. Mucci-LoRusso, L. Polin 37

Design of some nucleic acid antimetabolites: Expectations and reality – J.P. Horwitz 51

Biochemical mechanisms in colon xenografts: Thymidylate synthase as a target for therapy – P.J. Houghton, J.A. Houghton, B.J. Hazelton, S. Radparvar 59

Clinical trials with fluorinated pyrimidines in patients with head and neck cancer – M. Al-Sarraf 71

Dynamic management of squamous cell cancer of the anal canal – N.D. Nigro, V.K. Vaitkevicius, B. Considine Jr. 83

Cancer of the *Esophagus*: The Wayne State University experience – L. Leichman 91

The clinical syndrome of 5-fluorouracil cardiotoxicity – J.F. Ensley, B. Patel, R. Kloner, J.A. Kish, J. Wynne, M. Al-Sarraf 101

5-Fluorouracil radiation sensitization - A brief review – J.E. Byfield 111

Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors – A.-M. Maddox, M.J. Keating, E.J. Freireich, M.K. Haddox 119

2-Deoxy-d-glucose inhibits the antitumor effects of α-difluoromethylornithine on the growth of colon cancer *in vivo* – R. Saydjari, J.R. Upp Jr., R.W. Alexander, S.C. Barranco, C.M. Townsend Jr., J.C. Thompson 131

Disposition of 2′,3′-dideoxyadenosine and 2′3′-dideoxyinosine in mice – S.M. El Dareer, K.F. Tillery, J.R. Kalin, D.L. Hill 139

Cytotoxicity of synthetic racemic ptilocaulin: A novel cyclic guanidine – R.L. Ruben, B.B. Snider, F.W. Hobbs Jr., P.N. Confalone, B.A. Dusak 147

Heterogeneous survival and cell kinetics responses of human astrocytoma clones to α-difluoromethylornithine *in vitro* – S.C. Barranco, P.J. Ford, C.M. Townsend Jr. 155

Schedule-dependency of *in vivo* modulaton of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma – J.C. Nadal, C.J. van Groeningen, H.M. Pinedo, G.J. Peters 163

Experimental antitumor activity of BMY-28090, a new antitumor antibiotic – J.E. Schurig, W.T. Bradner, G.A. Basler, W.C. Rose 173

The effects of the anti-tumor agent mezerein on the cytotoxic capacity and oxidative metabolism of human blood cells – K. Barton, G. Randall, A.L. Sagone Jr. 179

Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer – E.S. Casper, T. Curley, T.B. Hakes 189

Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity – J.L. Abbruzzese, S. Schmidt, M.N. Raber, J.K. Levy, A.M. Castellanos, S.S. Legha, I.H. Krakoff 195

Phase I study of vincristine and escalating doses of etoposide – D.V. Jackson Jr., J.M. Cruz, P.J. Zekan, M.E. Caponera, C.L. Spurr, D.R. White, F. Richards II, H.B. Muss 203

Phase I study of 4′-deoxydoxorubicin (esorubicin) in children with malignant solid tumors – C.B. Pratt, E.C. Douglass, W.H. Meyer, F.A. Hayes, M.E. Horowitz, E.I. Thompson, L. Avery 209

Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative – K. Inoue, M. Ogawa, N. Horikoshi, T. Mukaiyama, Y. Itoh, K. Imajoh, H. Ozeki, D. Nagamine, K. Shinagawa 213

A Phase II study of spirogermanium in patients with advanced malignant lymphoma – C. Sessa, W. ten Bokkel Huinink, M. Clavel, L.M. Lev, R.A. Joss, J. Renard, F. Cavalli 219

Phase II trial of spirogermanium in advanced non-small cell lung cancer – T.E. Lad, R.R. Blough, M. Evrard, D.P. Shevrin, M.A. Cobleigh, C.M. Johnson, P. Hange 223

Phase II evaluation of gallium nitrate by continuous infusion in breast cancer – K. Jabboury, D. Frye, F.A. Holmes, G. Fraschini, G. Hortobagyi 225

Elliptinium: Phase II study in advanced measurable breast cancer – J. Treat, A. Greenspan, A. Rahman, M.S. McCabe, P.J. Byrne 231

Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study – W.P. McGuire, J.A. Blessing, E. Yordan, J. Beecham 235

Phase II trial of PCNU in breast carcinoma – J.M. Rubins, S.G. Taylor 239

Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer – C.K. Osborne, J.B. Craig, K. Klein, E.D. Crawford, J. Turner 243

Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group Phase II trial – B. Dana, S. Dahlberg, B. Schnitzer, C.R. Kjeldsberg, S.E. Jones, J. Carden, R. Mundis, B. Tranum 247

Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council study – D.H. Shevrin, T.E. Lad, L.J. Kilton, M.A. Cobleigh, R.R. Blough, L.L. Weidner, N.J. Vogelzang 251

Phase II trial of continuous drug infusions in advanced ovarian carcinoma: Acivicin versus vinblastine – R.H. Earhart, J.D. Khandekar, D. Faraggi, R.A. Schinella, T.E. Davis 255

Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector – C.I. Falkson, H.C. Falkson, G. Falkson 261

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study – M.A. Runge-Morris, M.S. Kies, E. Vokes, R. Blough, L. Weidner, R. Knop, K. Rowland 269

Cardiovascular rhythm effects of gamma recombinant DNA interferon – G.G. Friess, T.D. Brown, R.C. Wrenn 275

Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma – C.L. Arteaga, G.M. Clark 281

Migratory thrombophlebitis during sandostatin (SMS 201–995, Sandoz) therapy for malignant carcinoid syndrome – L. Nathanson, A. Sochet, M.E. Williams 285

Activity of batracylin (NSC-320846) against solid tumors of mice – P. Mucci-LoRusso, L. Polin, M-C. Bissery, F. Valeriote, J. Plowman, G.D. Luk, T.H. Corbett 295

Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines – P.B. Jensen, H. Roed, L. Vindeløv, I.J. Christensen, H.H. Hansen 307

Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study – E.K. Rowinsky, L.B. Grochow, A. Hantel, D.S. Ettinger, B.L. Vito, R.C. Donehower 317

Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS) – A. Chachoua, M. Green, J. Wernz, F. Muggia 327

Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study – W.P. McGuire, J.A. Blessing, M.L. Berman 333

A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix – a Gynecologic Oncology Group study – R.E. Slayton, J.A. Blessing, M. Rettenmaier, H. Ball 337

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study – G.P. Sutton, J.A. Blessing, L. Adcock, K.D. Webster, T. DeEulis 341

Sixth NCI-EORTC symposium on new drugs in cancer therapy abstracts 347